.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX41_Eribulin.Eribulin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX41_Eribulin.Eribulin| name: | Eribulin |
| ATC code: | L01XX41 | route: | intravenous |
| n-compartments | 3 |
Eribulin is a microtubule dynamics inhibitor, used as an anticancer drug primarily for the treatment of metastatic breast cancer and liposarcoma. It is a synthetic analog of halichondrin B and is approved for clinical use in multiple countries.
Mean pharmacokinetic parameters in adult patients with advanced solid tumors, primarily female, following intravenous administration.
Devriese, LA, et al., & Schellens, JH (2013). Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. British journal of clinical pharmacology 75(2) 507–515. DOI:10.1111/j.1365-2125.2012.04381.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22803519
Yu, Y, et al., & Wong, YN (2013). Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice. International journal of pharmaceutics 443(1-2) 9–16. DOI:10.1016/j.ijpharm.2013.01.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23313921
Hayato, S, et al., & Yasuda, S (2025). Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. Journal of clinical pharmacology 65(6) 751–762. DOI:10.1002/jcph.6187 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39853764